Vasculitis & polymyalgia rheumatica

PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study

Rheumatology (Oxford)Published Prospective cohort study

Main finding · New angiographic lesionsResult — go to the resultHazard ratio 7.56 95% CI 2.20–26.01

Authors' conclusion

PETVAS showed good performance in predicting new lesions in Takayasu arteritis.

Study context

Population
Chinese patients with newly diagnosed TAK, followed up for at least 2 years
Participants
82 patients
Exposure
Baseline PET vascular activity scores (PETVAS) ≥8 vs lower PETVAS
Outcome
New angiographic lesions on magnetic resonance angiography
Methodological detailsmultivariate Cox regression
  • Multivariate Cox regression

Main finding

New angiographic lesions

Hazard ratio

7.56

95% CI 2.20–26.01

P < 0.01

PETVAS ≥8vs PETVAS <8
HR 7.56 (95% CI 2.20–26.01); P < 0.01

As reported in the abstract

Observational data: associations, not effects.

Further findings

Incidence of new lesions (whole cohort) · median follow-up 36 months

Patients with new lesions
18 (22%)
Median time to first new lesion (months)
18

Correlation of PETVAS with ESR and CRP at baseline

PETVAS vs ESR, r
0.74, P < 0.01
PETVAS vs CRP, r
0.69, P < 0.01

Characteristics, without vs with new lesions

Female (without vs with new lesions)
67.2% vs 94.4%, P = 0.03
ESR (without vs with new lesions)
20 vs 49, P = 0.02
Active disease (without vs with new lesions)
62.5% vs 94.4%, P < 0.01

Safety

Adverse events including arterial ischaemic events · during follow-up

More likely in patients with PETVAS ≥8 at baseline

Original publication

PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study. Rheumatology (Oxford). Published 6 February 2023. doi:10.1093/rheumatology/kead056

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.